1. What Is the Urology Drug Market?
The Urology Drug Market covers the medicines used to treat the genitourinary conditions affecting the bladder, urethra, prostate, kidney collecting system, and the male and female reproductive organs. These include benign prostatic hyperplasia, overactive bladder, stress and urgency urinary incontinence, interstitial cystitis, erectile dysfunction, and testosterone deficiency. The urological cancers including prostate, bladder, and kidney cancer are managed with the systemic and localised treatments that each urological condition requires. Urology drug development has been transformed by the CRPC metastatic castration-resistant prostate cancer targeted therapy expansion. The androgen receptor pathway inhibitors abiraterone, enzalutamide, apalutamide, and darolutamide and the PARP inhibitors olaparib and rucaparib for the BRCA-mutated prostate cancer have extended the treatment options. The PSMA-targeted radioligand therapy lutetium-177 PSMA-617 has further extended the options across the prostate cancer treatment continuum. The urology drug market is being expanded by the beta-3 adrenoceptor agonist vibegron and mirabegron for overactive bladder that provide the antimuscarinic-free option with the cardiovascular safety profile that the elderly overactive bladder patient prefers. The PSMA PET imaging with gallium-68 PSMA-11 and fluorine-18 piflufolastat enables the precision staging and the treatment selection that guides the PSMA-targeted therapy patient selection.
2. Urology Drug Market Size & Forecast
3. Emerging Technologies
- Lutetium-177 PSMA-617 approval for metastatic CRPC demonstrated 7.7-month radiographic PFS improvement over standard care in the VISION trial. The theranostic approach integrates the PSMA PET imaging that identifies the patients whose tumours express PSMA at sufficient density for the radiolabelled PSMA ligand to deliver the cytotoxic lutetium-177 radiation to the metastatic sites. The same molecular targeting principle serves both the diagnostic imaging and the therapeutic irradiation.
- Androgen receptor pathway inhibitor sequential therapy in prostate cancer from the enzalutamide or apalutamide non-metastatic CRPC treatment through the metastatic CRPC progression demonstrates the treatment algorithm. The sequential loss of AR pathway sensitivity drives the escalation to the mechanisms that overcome the AR resistance. Cabazitaxel chemotherapy and the lutetium PSMA therapy are the subsequent options when the AR pathway inhibitors lose activity. The sequenced treatment continuum extends the survival of the CRPC patient population beyond what was achievable before the multiple AR pathway inhibitors became available.
- Overactive bladder beta-3 agonist vibegron and mirabegron pharmacologically differentiate from the antimuscarinic agents tolterodine and oxybutynin. The antimuscarinics cause the dry mouth, the constipation, the urinary retention, and the cognitive impairment that the elderly OAB population is most susceptible to. The beta-3 agonist acts on the detrusor muscle relaxation through the different receptor pathway that does not share the muscarinic side effect profile. The anticholinergic burden avoidance makes the beta-3 agonist the preferred OAB pharmacological option for the elderly patient taking multiple anticholinergic medications.
- Interstitial cystitis painful bladder syndrome treatment options include the intravesical heparin and dimethyl sulfoxide instillation, the oral pentosan polysulfate, and the neuromodulation that the sacral nerve stimulator provides for the refractory cases. The limited treatment success that this chronic pelvic pain condition achieves reflects the unmet medical need. No approved treatment achieves adequate control in the majority of patients. The unmet medical need characterises this condition that requires a multimodal management approach across urology, pain medicine, and pelvic floor physiotherapy.
Comparable technologies are influencing adjacent market segments in similar ways. Read more in our Specialty Drug Market.
4. Key Market Opportunity
Material revenue potential in the Urology Drug market is PSMA-targeted radiopharmaceutical therapy, where lutetium-PSMA and advancing pipeline compounds extend precision theranostic treatment into metastatic castration-resistant prostate cancer. Companies with PSMA-targeted platforms including Novartis capture this growing oncology urology intersection. Adjacent demand centers on next-generation OAB therapies improving tolerability. As PSMA-targeted therapy grows and OAB treatment advances, the addressable opportunity is expanding from generic BPH and OAB toward precision prostate cancer theranostics and tolerable OAB management.
5. Top Companies in the Urology Drug Market
The following organisations hold leading positions in the Urology Drug Market. The full report provides revenue share, SWOT analysis, and competitive benchmarking for each player.
- Astellas Pharma
- Pfizer
- GSK
- Boehringer Ingelheim
- Endo Pharmaceuticals
- Sun Pharma
- AbbVie
- Apellis Pharmaceuticals
- Sumitomo Pharma
- Antares Pharma
- Urogen Pharma
6. Market Segmentation
The Urology Drug Market is analysed across 3 segmentation dimensions. Revenue data, growth rates, and competitive intensity by sub-segment are available in the full report.
| Segmentation | Sub-Segments |
|---|---|
| By Indication | BPH OAB Erectile Dysfunction UTI Prostate Cancer |
| By Drug Class | Alpha Blocker Antimuscarinic Beta-3 Agonist PDE5 Inhibitor 5-ARI |
| By Geography | North America Europe Asia Pacific Latin America Middle East and Africa |
7. Key Market Trends (2026–2034)
Three major forces are shaping the Urology Drug Market trajectory over the forecast period:
Lutetium-177 PSMA-617 Pluvicto VISION Trial 7.7-Month PFS Improvement Has Established the Theranostic Approach Where PSMA PET Imaging Identifies Patients Whose Tumour PSMA Expression Enables the Radiolabelled Ligand to Deliver Cytotoxic Radiation to Metastatic Sites.Urovant Sciences and Sumitomo's vibegron Vibegron demonstrated non-superior but numerically comparable reduction in daily urgency episodes to tolterodine ER in EMPOWUR with significantly fewer anticholinergic adverse events including dry mouth and constipation that cause discontinuation in approximately 30-40% of antimuscarinic-treated patients. The beta-3 agonist mechanism increases bladder capacity through smooth muscle relaxation without the salivary gland, gut, and CNS anticholinergic effects that limit antimuscarinic dosing and adherence in elderly patients where OAB prevalence is highest and anticholinergic burden from polypharmacy is clinically significant. Vibegron's approval at a standard once-daily dose without renal or hepatic adjustment requirements, and its absence from the Beers Criteria inappropriate medication list for elderly patients, creates prescribing advantages in geriatric urology where antimuscarinic avoidance guidelines have left OAB systematically undertreated.
AR Pathway Inhibitor Sequential Therapy Algorithm From Non-Metastatic CRPC Through Metastatic CRPC to Lutetium PSMA Demonstrates the Treatment Continuum Where Sequential AR Pathway Resistance Drives the Escalation to Mechanisms That Overcome the Resistance.Pfizer's enzalutamide ARAMIS and Johnson and Johnson's apalutamide SPARTAN demonstrated metastasis-free survival improvements of over 22 months in nmCRPC when PSA doubling time was below 10 months, and ARCHES and ENZAMET established enzalutamide superiority over bicalutamide in metastatic hormone-sensitive prostate cancer. The commercial expansion across disease states from docetaxel-naive metastatic CRPC through nmCRPC to mHSPC has extended enzalutamide's addressable population more than tenfold compared with the castration-resistant metastatic indication where it was initially approved. The competitive landscape in advanced prostate cancer now includes five approved next-generation AR inhibitors, and the prescribing decision among enzalutamide, apalutamide, darolutamide, abiraterone, and relugolix combinations is driven by drug interaction profiles, cardiovascular risk, and treatment setting rather than efficacy differentiation among agents that achieve broadly similar outcomes.
Beta-3 Agonist Vibegron and Mirabegron Providing Anticholinergic-Free OAB Treatment Is Addressing the Dry Mouth, Cognitive Impairment, and Urinary Retention That the Elderly OAB Population Cannot Tolerate From the Muscarinic Antagonist Side Effect Profile.Medtronic's InterStim Micro rechargeable SNM system and the wireless InterStim X eliminate the previous requirement for an external stimulator, enabling complete subcutaneous implantation that resolves the lifestyle restrictions associated with bulky external components. Uroplasty's Urgent PC percutaneous tibial nerve stimulation provides office-based neurostimulation without surgical implantation, delivering 30-minute weekly sessions for 12 weeks that achieve durable OAB symptom reduction equivalent to SNM in appropriately selected patients. The treatment algorithm positioning SNM and PTNS after failed pharmacotherapy and before bladder augmentation surgery creates a procedural opportunity in approximately 15-20% of OAB patients who are pharmacotherapy-refractory, and the rechargeable battery innovation extending device lifespan from 3-5 to 15-plus years has significantly improved the cost-effectiveness of SNM implantation.
For related market intelligence, see the Pharmaceutical Market.
8. Segmental Analysis
By indication, the overactive bladder segment dominated the Urology Drug Market in 2025, as antimuscarinic agents and Astellas Pharma's Myrbetriq and Vibegron anchored treatment of the large symptomatic population, generating the largest share of urology revenue across primary and specialty care.
By drug class, the beta-3 adrenoceptor agonist segment is projected to register the highest growth rate through 2034, as improved-tolerability bladder agents displace antimuscarinics, while Urogen Pharma's intravesical therapies expand treatment into upper-tract urothelial disease and overactive bladder in underserved patient groups.
9. Regional Analysis
Regional demand patterns across the Urology Drug Market reflect differences in regulation, technological maturity, and capital investment.
Largest Market Share
North America dominated the Urology Drug Market in 2025, accounting for approximately 48% of global revenue, attributed to the US premium pricing for beta-3 agonist OAB therapies and PSMA-targeted prostate cancer drugs and the concentration of major urology drug companies. Moreover, PSMA theranostic adoption and OAB beta-3 prescribing are most advanced in the US. In addition, the large prostate cancer patient population sustains targeted oncology demand. Regional dominance is due to this combination of pricing environment and innovation adoption.
Highest CAGR Region
Asia Pacific is projected to register the highest CAGR in the Urology Drug Market through 2034, driven by the ageing male population in China, Japan, and South Korea with rising BPH and prostate cancer prevalence and expanding pharmaceutical access and urology healthcare. The region is also witnessing OAB drug adoption growing with diagnosis. Moreover, prostate cancer drug penetration is increasing. The combination of these demand drivers and demographic ageing positions Asia Pacific for sustained growth outperformance through 2034.
10. Full Report with Exclusive Insights
The complete published market report includes an in-depth analysis of market dynamics, industry trends, competitive landscape, regional outlook, and future growth opportunities. The study provides detailed market sizing and forecasts across key segments and geographies, along with comprehensive insights into drivers, restraints, opportunities, challenges, technological advancements, regulatory landscape, and evolving consumer and industry trends. The report also features company profiles, strategic developments, market share analysis, and actionable recommendations to support informed business decision-making. Additionally, the syndicated report package typically includes forecast datasets, charts and figures, research methodology, and analyst support for strategic interpretation and planning.
Advanced Strategic & Custom Intelligence
In addition to the standard syndicated report package, TrendX Insights can provide the following advanced strategic analyses and customized intelligence solutions for any market:
Standard Report Coverage
- • Competitor Analysis
- • Country Trade Analysis
- • Import & Export Analysis
- • Porter’s Five Forces Analysis
- • SWOT Analysis by Companies
- • TrendX Insights Quadrant Positioning
- • Pricing Analysis
- • Detailed Macro-Economic Indicators Assessment
- • List of Raw Material Suppliers
- • Regulatory Framework Assessment
- • Supply Chain Resilience Mapping
- • Value Chain Analysis
- • Technology adoption trends and innovation tracking
- • Custom company profiling and benchmarking
Exclusive Sections With Additional Cost
- • Agentic AI Readiness Score
- • TAM, SAM, and SOM Analysis
- • AI Act & Privacy Compliance Audit
- • Channel Partner Ecosystem Mapping
- • China + 1 Strategy Analysis
- • Circular Economy Opportunities Assessment
- • Competitor Benchmarking KPI Analysis
- • Country Trade Analysis
- • Country-level opportunity mapping
- • Digital Maturity Matrix
- • Ecosystem Interdependency Mapping
- • ESG & Decarbonization Roadmap
- • Geopolitical Friction Scorecard
- • Geopolitical Risk Assessment
- • Humanoid Workforce Impact Analysis
- • Investment Heatmap
- • List of Distributors and Channel Partners
- • List of Raw Material Suppliers
- • Market Entry Strategy Assessment
- • Mergers & Acquisitions (M&A) Analysis
- • Patent & Intellectual Property (IP) Analysis
- • Pilot Project Analysis
- • Potential High-Growth Region/Country Investment Assessment
- • Product Comparison Analysis
- • Product Revenue Analysis
- • R&D Investment Analysis in Emerging Technologies
- • Raw Material Scarcity Forecast
Note: For highly customized requirements, deeper strategic assessments, company-specific intelligence, or tailored consulting support, please contact TrendX Insights.
Full Report with Exclusive Insights
Available to clients on request
Explore Our Published Reports Library
This page covers market-level data estimates. For comprehensive published research reports including full methodology, primary data, and detailed company profiles, browse the TrendX Insights Published Reports Library.
Visit Published Reports Library ›11. Related Market Reports
Frequently Asked Questions
The Urology Drug Market was valued at USD 18.42 Bn in 2025 and is projected to reach USD 29.82 Bn by 2034, growing at a CAGR of 5.5% over the 2026–2034 forecast period.
The Urology Drug Market is projected to grow at a CAGR of 5.5% from 2026 to 2034.
North America dominated the Urology Drug Market in 2025, accounting for approximately 48% of global revenue, attributed to the US premium pricing for beta-3 agonist OAB therapies and PSMA-targeted prostate cancer drugs and the concentration of major urology drug companies.
The leading companies in the Urology Drug Market include Astellas Pharma, Pfizer, GSK, Boehringer Ingelheim, Endo Pharmaceuticals, Sun Pharma, AbbVie, Apellis Pharmaceuticals, Sumitomo Pharma, Antares Pharma, Urogen Pharma.
Lutetium-177 psma-617 pluvicto vision trial 7.7-month pfs improvement has established the theranostic approach where psma pet imaging identifies patients whose tumour psma expression enables the radiolabelled ligand to deliver cytotoxic radiation to metastatic sites.
By indication, the overactive bladder segment dominated the Urology Drug Market in 2025, as antimuscarinic agents and Astellas Pharma's Myrbetriq and Vibegron anchored treatment of the large symptomatic population, generating the largest share of urology revenue across primary and specialty care.
How to Order
Purchasing a TrendX Insights report is straightforward. Our process is designed to be transparent and risk-free for buyers, with a 20% upfront model and full delivery before the balance payment.
This is the price of the syndicated report. Any custom inclusions beyond the Table of Contents will be scoped and priced separately. For the full list of what is covered in the syndicated report, refer to the Table of Contents tab.
A curated, condensed version of this report for students, researchers, and academic institutions. Ideal for thesis work, dissertations, and academic projects. Delivered as PDF to your institutional email.
Valid student ID or institutional email required. For educational and non-commercial use only.